ALLMedicine™ Angina Pectoris Center
Research & Reviews 1,746 results
https://doi.org/10.1161/JAHA.122.028423
Journal of the American Heart Association; Berntorp K, Rylance R et. al.
Feb 4th, 2023 - Background Although physiology-based assessment of coronary artery stenosis using instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) are established methods of guiding coronary revascularization, its clinical outcome in long-ter...
https://doi.org/10.1007/s12325-023-02425-0
Advances in Therapy; Zhao X, Tong Z et. al.
Feb 4th, 2023 - Angina pectoris (AP) is the initial and the most common manifestation of coronary artery disease (CAD). Therefore, management and control of AP can help prevent further complications associated with CAD. However, there is under-reporting of angina...
https://doi.org/10.1097/CRD.0000000000000516
Cardiology in Review; Paz Y, Grosman-Rimon L et. al.
Feb 3rd, 2023 - The Neovasc Coronary Sinus Reducer Stent (CSRS) was developed for the treatment of patients who continue to suffer from disabling symptoms despite optimal medical therapy. This patient population with refractory angina symptoms is expected to grow...
https://clinicaltrials.gov/ct2/show/NCT04144725
Feb 1st, 2023 - This is an observational study of patients with suspected coronary artery disease referred to coronary computed tomography angiography (CCTA). The plan is to include 1000 patients prior to CCTA at two centers. Blood samples for biomarker measureme...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884407
BMC Cardiovascular Disorders; Zhao R, Luo S et. al.
Jan 29th, 2023 - Addison's disease which is due to dysfunction of the adrenal gland, with abnormal secretion of glucocorticoids and mineralocorticoids, is rare. By inducing inflammation and disorders of water and electrolyte metabolism, Addison's disease may accel...
Guidelines 3 results
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.
Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723022
The Canadian Journal of Cardiology; McGillion M, L'Allier PL et. al.
Jul 9th, 2009 - Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.|2009|McGillion M,L'Allier PL,Arthur H,Watt-Watson J,Svorkdal N,|epidemiology,therapy,epidemiology,
https://onlinelibrary.wiley.com/doi/abs/10.1111/fcp.12633
Fundamental & Clinical Pharmacology; Ala M, .
Sildenafil, approved two decades ago, is the inhibitor of phosphodiesterase 5 (PDE5). First of all, it was designated for angina pectoris, but soon it showed a wonderful efficacy in erectile dysfunction (ED) and then pulmonary arterial hypertensio...
Drugs 940 results see all →
Clinicaltrials.gov 296 results
https://clinicaltrials.gov/ct2/show/NCT04144725
Feb 1st, 2023 - This is an observational study of patients with suspected coronary artery disease referred to coronary computed tomography angiography (CCTA). The plan is to include 1000 patients prior to CCTA at two centers. Blood samples for biomarker measureme...
https://clinicaltrials.gov/ct2/show/NCT05682118
Jan 19th, 2023 - In coronary angiography, 50% or more stenosis of the causative vessel is observed in a patient with stable angina pectoris (SAP) or 50% or more stenosis of a non-causative vessel is observed in acute coronary syndrome (ACS) Based on 0.90, if it is...
https://clinicaltrials.gov/ct2/show/NCT05623995
Jan 18th, 2023 - Chronic total occlusions (CTOs) are found in 15-25% of patients with stable angina pectoris. The presence of a CTO indicates unfavorable prognosis, with higher rate of major adverse cardiovascular events. Statins are frequently used after PCI in o...
https://clinicaltrials.gov/ct2/show/NCT05647148
Dec 12th, 2022 - The data of this study will be collected between May 2022 and December 2022. The research will be carried out with a total of 60 (experimental group=30, control group=30) patients treated for heart failure, myocardial infarction and angina pectori...
https://clinicaltrials.gov/ct2/show/NCT01735825
Dec 8th, 2022 - In-stent restenosis after coronary angioplasty is currently one of the main limitations of this method, leading to a recurrence of exertional angina pectoris or manifesting as acute coronary syndrome. Histopathologic substrate of in-stent restenos...
News 123 results
https://www.medscape.com/viewarticle/982935
Oct 24th, 2022 - Results from an observational study exploring the link between dairy intake and risk of cardiovascular disease events in patients with stable angina pectoris suggest different dairy products may have different health effects. The study, which anal...
https://www.onclive.com/view/amcenestrant-provides-numerically-similar-pfs-to-endocrine-therapy-in-endocrine-resistant-er-advanced-breast-cancer
Sep 10th, 2022 - Amcenestrant (SAR439859) did not significantly improve progression-free survival (PFS) over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor (ER)–positive, HER2-negative advanced breast cancer, bu...
https://www.onclive.com/view/eu-approves-asciminib-for-ph-cml-in-chronic-phase-after-2-or-more-tkis
Aug 29th, 2022 - The European Commission (EC) has approved asciminib (Scemblix) for the treatment of patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML) in chronic phase who received prior treatment with at least 2 TKIs.1 The appr...
https://www.onclive.com/view/orteronel-plus-adt-misses-os-end-point-in-metastatic-hormone-sensitive-prostate-cancer
May 20th, 2022 - The addition of orteronel (TAK-700) to androgen deprivation therapy (ADT) vs bicalutamide improved progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic hormone-sensitive prostate cancer (mHSPC), ...
https://www.mdedge.com/internalmedicine/article/253888/mens-health/real-world-data-suggest-coprescribing-pde5-inhibitors
Will Pass
Apr 19th, 2022 - As coprescribing drugs for erectile dysfunction and oral organic nitrates for ischemic heart disease (IHD) surged, cardiovascular adverse events did not significantly increase, a new study finds. The authors of the new research specifically examin.